BeOne Medicines Ltd. Class A
SHH: 688235.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John V. Oyler
- Employees
- 11,000
- Headquarters
- Basel, Switzerland
- IPO year
- 2021
- Market cap
- CN¥258.8B
- Website
- https://beonemedicines.com
Loading 688235…
Loading profile data…Frequently asked questions about 688235
What does BeOne Medicines Ltd. Class A (688235.SS) do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA...
Where does 688235.SS trade?
BeOne Medicines Ltd. Class A (688235.SS) trades on the Shanghai Stock Exchange.
What sector is 688235.SS in?
BeOne Medicines Ltd. Class A (688235.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BeOne Medicines Ltd. Class A?
John V. Oyler is the chief executive officer of BeOne Medicines Ltd. Class A (688235.SS).
Where is BeOne Medicines Ltd. Class A headquartered?
BeOne Medicines Ltd. Class A is headquartered in Switzerland.
Does 688235.SS pay a dividend?
BeOne Medicines Ltd. Class A (688235.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 688235.SS go public?
BeOne Medicines Ltd. Class A (688235.SS) completed its initial public offering in 2021.